证券代码：000525 证券简称：ST 红太阳 公告编号：2023－064 公司董事关于 2023 年半年度报告的书面确认意见： 根据《证券法》的要求，本人作为公司的董事，保证公司 2023 年半年度报告内容真实、准确、完整，不存在任何虚假记载、误导性 陈述或者重大遗漏。 南京红太阳股份有限公司 第九届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 南京红太阳股份有限公司（以下简称"公司"）第九届董事会第八 次会议于 2023 年 8 月 29 日以通讯方式召开。本次会议通知于 2023 年 8 月 19 日以书面、邮件或通讯等方式发出。本次会议应参加表决 董事 9 名，实际参加表决董事 9 名。本次董事会会议材料同时提交公 司监事及高级管理人员审阅。会议的召集和召开符合《公司法》和《公 司章程》等有关规定。会议审议并通过了以下议案： 一、审议并通过了《公司 2023 年半年度报告及摘要》。 董 事 会 2023 年 8 月 29 日 具体内容详见同日公司在巨潮资讯网披露的《公司 2023 年半年 度报告》和《公司 2023 年半年度 ...

证券代码：000525 证券简称：ST 红太阳 公告编号：2023-062 南京红太阳股份有限公司 关于签署《关于参与南京红太阳股份重整投资之意向协议书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、2023 年 8 月 17 日，南京红太阳股份有限公司（以下简称"公司"）与湖北 同富创业投资管理有限公司（以下简称"湖北同富投资"）、预重整管理人签署《关 于参与南京红太阳股份重整投资之意向协议书》（以下简称"《重整投资意向协议》" 或"本协议"）。 2、本次签署的《关于参与南京红太阳股份重整投资之意向协议书》仅为意向 协议，本次重整过程中，各方将根据实际需要签署相关正式协议，具体投资方案 以经湖北同富投资主管国有资产监督管理机构审批通过、南京市中级人民法院裁 定批准的重整计划及各方签署的正式投资协议为准。 3、截至本公告日，公司正在进行预重整，预重整为法院正式受理重整前的程 序，法院最终能否裁定公司进入重整程序尚存在不确定性，重整是否成功也存在 不确定性。敬请广大投资者注意投资风险。 2022 年 9 月 16 日，公司收到南京市中级 ...

Market Overview - The global pesticide market faced significant challenges in the first half of 2023 due to adverse factors such as climate anomalies in North and South America, the escalation of the Russia-Ukraine conflict, and the impact of U.S. interest rate hikes, leading to a substantial decline in market demand compared to the previous year [2] - The prices of glyphosate and glufosinate have dropped significantly, causing a decrease in the overall pesticide market prices and a sluggish transaction volume [2] Product Performance - Despite being banned in some countries, paraquat is still widely used in regions like the U.S., South America, Indonesia, and Africa due to its unique properties as a herbicide [2] - The price of paraquat has stabilized and rebounded recently after a decline influenced by the drop in glyphosate prices [2] New Product Development - The company is actively promoting new products such as dichlorophenoxyacetic acid and chlorantraniliprole, aiming to create new growth [2][3] - The L-glufosinate product has a higher activity level, being over twice as effective as traditional glufosinate, and can reduce application rates by 50%, aligning with national pesticide reduction policies [3] Cost Advantages - The company has developed a cost-effective production process for chlorantraniliprole, utilizing its proprietary intermediate, which results in lower costs and energy savings [3] - The annual production capacity of chlorantraniliprole is set at 2,000 tons, with successful production already established [3] Strategic Response - The company has implemented strategies to adapt to the challenging market conditions, focusing on core business, optimizing product structure, and enhancing operational efficiency [3] - The ongoing pre-restructuring process aims to resolve debt and historical issues, optimizing the company's financial structure and enhancing sustainable development [3]

Financial Performance - The company reported a significant decline in revenue, with total revenue for 2022 amounting to RMB 1.2 billion, a decrease of 15% compared to the previous year[19]. - The net loss for the year was RMB 300 million, representing a loss margin of 25%[19]. - The company's operating revenue for 2022 was ¥6,439,912,658.86, representing a 37.51% increase compared to ¥4,683,382,031.58 in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥732,297,405.94, a significant turnaround from a loss of ¥3,744,122,363.59 in 2021, marking a 119.56% improvement[24]. - The net cash flow from operating activities for 2022 was ¥1,142,420,374.26, up 227.68% from ¥348,634,781.59 in 2021[24]. - The basic earnings per share for 2022 was ¥1.2609, a recovery from a loss of ¥6.4468 per share in 2021[24]. - The total assets at the end of 2022 were ¥10,280,802,563.89, a 5.90% increase from ¥9,707,619,065.78 at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were ¥1,271,285,338.83, up 129.50% from ¥553,945,905.99 at the end of 2021[24]. - The company reported a weighted average return on equity of 43.47% for 2022, recovering from -174.73% in 2021[24]. - The gross margin improved to 35%, up from 30% in the previous year, due to cost optimization strategies[59]. Research and Development - Research and development expenses increased by 10% year-on-year, totaling RMB 120 million, reflecting the company's commitment to innovation[19]. - The company is committed to increasing investment in new product and technology development to accelerate product upgrades[43]. - The company holds numerous patents, including 15 invention patents and several utility model patents, enhancing its R&D capabilities and competitive edge in the market[46]. - The company has established a comprehensive technological innovation system for the green pesticide industry, with 4 national-level R&D platforms and 8 provincial-level R&D platforms[66]. - R&D investment amounted to ¥285,370,357.43 in 2022, representing a significant increase of 69.96% compared to ¥167,903,109.85 in 2021, with R&D investment as a percentage of operating revenue at 4.43%[92]. - R&D personnel increased to 658 in 2022, a growth of 2.02% from 645 in 2021, with the proportion of R&D personnel rising to 22.30%[92]. Market Expansion and Strategy - The company plans to focus on expanding its product line, particularly in the pesticide sector, aiming for a 20% increase in market share by 2025[19]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[19]. - The company is focusing on expanding its green pesticide product lines and enhancing its supply chain through strategies like "extending, strengthening, and supplementing" the chain[42]. - The company plans to stabilize revenue growth by actively organizing production and exploring new markets[43]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[59]. - The company plans to enter the European market, with initial sales targets set at 100 million RMB in the first year[61]. Operational Efficiency - The company is implementing new strategies to improve operational efficiency, targeting a 10% reduction in operational costs by the end of 2023[19]. - The company aims to reduce operational costs by 10% through improved supply chain management initiatives[59]. - The company has achieved significant milestones in its judicial restructuring, enhancing asset strength and addressing historical issues, which will benefit investors and local governments[117]. - The company is transitioning to become the world's first "digital green biochemical pesticide" high-tech company, with a focus on integrating digital and biochemical technologies[118]. Environmental Compliance - The company is committed to environmental compliance, holding various permits including pollution discharge licenses valid until 2027[53]. - The company has implemented continuous discharge monitoring systems across its facilities to ensure compliance with environmental standards[188]. - The company has invested CNY 128 million to upgrade its wastewater treatment plant, increasing its capacity to 10,000 tons per day, meeting the highest national water pollutant discharge standards[191]. - The company has established a three-level environmental risk accident water pollution prevention system to ensure wastewater is collected and treated during emergency situations[198]. - The company is actively monitoring and managing its emissions to align with the latest environmental regulations and standards[189]. Governance and Management - The company has a strong emphasis on research and development, with key personnel in technical roles to support product innovation[146][147]. - The governance structure includes a board of directors with 9 members, including 3 independent directors, ensuring effective decision-making and risk management[133]. - The company has strengthened its internal control system, improving management levels significantly, although issues related to non-operating fund occupation remain unresolved[134]. - The company has established an independent financial department and accounting system, ensuring independent financial decision-making, with no shared bank accounts with the controlling shareholder[136]. - The company has emphasized the importance of independent directors in its governance structure, with the election of Wu Xuemin and Yan Zhen as independent directors[145]. Challenges and Risks - The company is under investigation by the China Securities Regulatory Commission for information disclosure violations, which may impact future operations[5]. - The company faces multiple risks, including market, climate, exchange rate, and safety/environmental risks, and has outlined strategies to mitigate these challenges[122][124]. - The company's stock has been under special risk warning since May 6, 2021, due to non-operating fund occupation by controlling shareholders and related parties, with the stock name changed to "ST Hongtai"[125]. - The company has not eliminated the non-operating fund occupation by controlling shareholders and related parties, and is urging repayment[182].

南京红太阳股份有限公司 证券代码：000525 证券简称：ST 红太阳 编号：2023-003 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类 □新闻发布会 □路演活动 别 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 中信建投证券-郭祝同、银河基金-盛兆 时间 2023 年 5 月 19 日 10：00 地点 公司会议室 上市公司 接待人员姓名 副总经理-王国平、董事会秘书-王露、证券部-唐志军 | --- | |--------------------------------------------------------------------| | 一、副总经理王国平先生对公司发展概况、主要产品和竞争力优势进 | | 行简要说明； | | 二、问答环节： | | 问题 1：面对今年农药行业下行周期的严峻形势，公司将如何应对？ | | 答：针对 2022 年下半年以来主要农药产品价格不断下降和全球主要 | | 农药市场前期处于高价"超买"状态导致的渠道库存消化缓慢的严峻形势， | | 公司坚持聚焦主业、坚定信心，立足发挥创业 34 年形成的生物化学技 ...

Financial Performance - The company reported a total revenue of 1.5 billion CNY for the year 2022, representing a year-on-year increase of 12%[141]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the fiscal year, representing a 15% year-over-year growth[61]. - The company’s operating revenue for 2022 was ¥6,439,912,658.86, representing a 37.51% increase compared to ¥4,683,382,031.58 in 2021[26]. - The net profit attributable to shareholders for 2022 was ¥732,297,405.94, a significant turnaround from a loss of ¥3,744,122,363.59 in 2021, marking a 119.56% increase[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥747,797,127.21, compared to a loss of ¥252,226,490.47 in the previous year, reflecting a 396.48% improvement[26]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[61]. - The revenue from the pesticide chemical sector accounted for 98.96% of total revenue, with a year-on-year growth of 36.40%[83]. - The company reported a total operating revenue for 2022 reached ¥6,439,912,658.86, representing a year-on-year increase of 37.51% compared to ¥4,683,382,031.58 in 2021[83]. Market Position and Strategy - The company is focusing on expanding its green pesticide product lines and enhancing its supply chain through strategies like "extending, strengthening, and supplementing" the industrial chain[44]. - The company aims to cultivate a number of large-scale production enterprises, with targets set for 2025 to have 10 companies with revenues exceeding CNY 5 billion[41]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[61]. - The company is exploring market expansion opportunities in both domestic and international markets to increase its overall market share[56]. - The company is actively pursuing new product registrations, with several key products set to expire in the next few years, ensuring a pipeline for future growth[58]. - The company is committed to enhancing safety and environmental responsibility in its production processes to minimize risks associated with hazardous materials[125]. Research and Development - The company holds numerous patents, including 15 invention patents and 8 utility model patents related to its core products, enhancing its R&D capabilities[48]. - Research and development investments increased by 30%, totaling 150 million CNY, focusing on innovative agricultural chemicals[61]. - The company is investing 200 million CNY in R&D for new technologies aimed at enhancing product efficiency and sustainability[141]. - The company has established a comprehensive technological innovation system for the green pesticide industry, with 4 national-level R&D platforms and 8 provincial-level R&D platforms[68]. - The company has successfully completed large-scale production of its proprietary products, including the herbicide "Diquat" and other new biopesticides, to meet market demands[78]. Internal Controls and Governance - The company reported a negative opinion audit report from Zhongxing Caiguanghua Accounting Firm, indicating issues with internal controls[4]. - The company identified two significant internal control deficiencies related to financial reporting during the reporting period[169]. - The company plans to enhance its internal control system and improve long-term mechanisms in 2023 to address identified deficiencies[169]. - The company has established a robust internal control system covering major operational activities, significantly improving management levels[135]. - The company maintains operational independence from its controlling shareholder, with a complete supply, production, and sales system[136]. Environmental Compliance - The company is committed to ongoing improvements in its waste management and emissions reduction strategies[188]. - The company has implemented a comprehensive air pollution control system, including SCR denitrification and various washing processes for exhaust gases from incinerators[196]. - The company has established a hazardous waste storage facility to manage hazardous waste generated during operations[193]. - The company is focused on reducing its environmental impact through continuous monitoring and compliance with pollution discharge standards[188]. - The company has installed online monitoring facilities for COD, ammonia nitrogen, total phosphorus, and total nitrogen at its wastewater treatment plant, ensuring real-time monitoring[193]. Challenges and Risks - The company is under investigation by the China Securities Regulatory Commission for information disclosure violations, with potential administrative penalties pending[5]. - The company faces multiple risks, including market, climate, exchange rate, and safety/environmental risks, and is implementing strategies to mitigate these challenges[123]. - The company has not completed rectification of the identified issues related to non-operating fund occupation and other receivables lacking reasonable commercial justification[178]. - The company is actively urging related parties to repay the non-operating funds, with ongoing rectification efforts[183]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[61]. - The company aims to leverage the stable growth in demand for green pesticides driven by food security needs, focusing on three key strategies: expanding domestic and international markets, enhancing efficiency through management innovation, and accelerating new project construction[45]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 500 million CNY allocated for potential mergers[61]. - The company has set a revenue guidance of 1.8 billion CNY for 2023, indicating a growth target of 20%[141].

Financial Performance - The company's operating revenue for Q1 2023 was ¥747,388,776.20, a decrease of 51.10% compared to ¥1,528,497,781.36 in the same period last year[3] - The net profit attributable to shareholders was ¥11,316,969.11, down 96.30% from ¥305,590,608.32 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥14,537,586.97, a decline of 95.38% compared to ¥314,700,365.59 in the previous year[3] - The net cash flow from operating activities was ¥67,421,620.44, representing a 53.01% decrease from ¥143,475,487.35 in the same period last year[3] - Total revenue for Q1 2023 was ¥747,388,776.20, a decrease of 51.1% compared to ¥1,528,497,781.36 in the same period last year[16] - Net profit for Q1 2023 was ¥7,697,450.67, compared to a net profit of ¥302,575,278.68 in Q1 2022, indicating a significant decline[16] - The net profit attributable to the parent company for Q1 2023 is ¥11,316,969.11, a decrease from ¥305,590,608.32 in the previous period[17] - The total comprehensive income attributable to the parent company is ¥11,316,969.11, compared to ¥305,590,608.32 in the previous period[17] - Basic and diluted earnings per share for Q1 2023 are both ¥0.0195, down from ¥0.5262 in the previous period[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,054,719,865.46, a decrease of 2.20% from ¥10,280,802,563.89 at the end of the previous year[3] - Total liabilities decreased to ¥8,633,361,219.71 from ¥8,882,507,428.55, reflecting a decline of 2.8%[14] - Current assets totaled ¥4,986,155,727.65, down 4.1% from ¥5,198,301,733.47 at the beginning of the year[14] - The company's total assets decreased to ¥10,054,719,865.46 from ¥10,280,802,563.89 at the beginning of the year, a reduction of 2.2%[14] - The company's equity attributable to shareholders increased to ¥1,287,580,388.51 from ¥1,271,285,338.83, a rise of 1.3%[14] Cash Flow - Cash inflow from operating activities for Q1 2023 is ¥734,286,535.82, a decrease from ¥1,581,523,644.29 in the previous period[18] - Cash outflow from investing activities is ¥46,071,836.62, compared to ¥29,156,992.09 in the previous period[19] - Net cash flow from financing activities is -¥91,247,603.18, an improvement from -¥100,805,780.36 in the previous period[19] - The ending cash and cash equivalents balance is ¥144,913,759.77, compared to ¥95,369,688.72 in the previous period[19] - The company received cash from sales of goods and services amounting to ¥558,357,780.45, down from ¥1,198,071,772.59 in the previous period[18] - The company paid cash to employees totaling ¥115,159,824.67, a decrease from ¥167,471,037.64 in the previous period[19] Expenses and Costs - Total operating costs for Q1 2023 were ¥754,331,508.01, down 37.0% from ¥1,194,201,409.70 year-over-year[16] - Research and development expenses for Q1 2023 were ¥45,162,420.36, down 22.7% from ¥58,433,681.04 in the previous year[16] - The company experienced a 72.14% reduction in selling expenses, which amounted to ¥10,348,110.37 compared to ¥37,149,599.69 in the same period last year[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,518[7] - The largest shareholder, Nanjing First Pesticide Group Co., Ltd., holds 31.50% of shares, totaling 182,924,731 shares[7] Corporate Actions and Investigations - Nanjing Hongtaiyun Business Co., Ltd. transferred its 51% stake in Anhui Hongtai Biological Chemical Co., Ltd. to Nanjing Huazhou Pharmaceutical Co., Ltd.[10] - The registered capital of Nanjing Xinzou Technology Co., Ltd. was set at 20 million RMB, with Nanjing Huazhou Pharmaceutical holding 49%[10] - The company’s shareholding in Zhongnong Hongtai (Nanjing) Biotechnology Co., Ltd. decreased from 42% to 10%[10] - The company is under investigation by the China Securities Regulatory Commission for information disclosure violations[9] - The company’s stock continues to be subject to "other risk warnings" as per the Shenzhen Stock Exchange regulations[9] - The company reported a significant amount of pledged and frozen shares among its major shareholders[8] Credit and Impairment - The company reported a significant increase in credit impairment losses, which rose by 284.12% to ¥17,985,354.58 compared to a loss of ¥9,768,175.31 in the previous year[6]

Group 1: Regulatory Impact and Product Development - Document 1745 regulates the management of paraquat, maintaining a stable future demand outlook for the company [1] - The new regulation requires re-approval of labels and changes to pesticide production approval documents, effective from January 1, 2013 [1] - The company’s subsidiary has registered a new formulation of paraquat, a soluble gel, with a validity period from September 25, 2013, to September 25, 2018 [2] Group 2: Product Comparison - Glyphosate, paraquat, and diquat have both commonalities and unique characteristics; glyphosate is a highly effective, low-toxicity herbicide [2] - Paraquat is known for its verticality and non-drifting properties, while diquat is recognized as an ideal environmentally friendly herbicide in developed countries [2] Group 3: Fundraising and Financials - The non-public offering aims to raise up to ¥1,038,187,464.77, with net proceeds intended for working capital and debt repayment [2] - The company distributed cash dividends of ¥0.2 per share in 2011, totaling ¥10,144,936.98 [3] - In 2012, the dividend was increased to ¥0.3 per share, amounting to ¥15,217,405.47 [3] - For 2013, the dividend was further raised to ¥0.5 per share, totaling ¥25,362,342.45 [3] Group 4: Sales and Market Strategy - Domestic sales are primarily through the Hongtai Agricultural Chain and Su Nong Chain, focusing on pesticide and fertilizer sales [2] - The company aims to accelerate the industrialization of downstream products in the pyridine industry chain, emphasizing the replacement of high-toxicity pesticides [3]

Group 1: Production Capacity and Raw Materials - The company's pyridine production capacity is 62,000 tons per year [1] - Main raw materials for pyridine production include formaldehyde, acetaldehyde, and liquid ammonia, which are affected by oil price fluctuations [1] - The ratio of pure pyridine to 3-methylpyridine in the production chain is 2:1 [1] Group 2: Product Sales and Market Focus - The company exports a significant portion of its paraquat products, with exports accounting for a large share [1] - Paraquat, glyphosate, and diquat have both common and unique characteristics; glyphosate is a highly effective, low-toxicity herbicide, while paraquat is known for its verticality and non-drifting properties [1] Group 3: Herbicide Characteristics - Glyphosate acts through absorption and translocation, effectively killing weeds by penetrating their waxy surface [1] - Paraquat is recognized for its excellent features such as soil preservation and rapid action [1] - Diquat is a fast-acting herbicide suitable for various agricultural applications, particularly effective in potato cultivation [1]

Group 1: Company Overview - Nanjing Hongtaiyang Co., Ltd. focuses on environmentally friendly pesticides, with products including herbicides, insecticides, fungicides, and intermediates [1] - The company has three main industrial chains: pyrethroid, pyridine, and hydrogen cyanide [1] Group 2: Production Capacity and Raw Materials - The production capacity of the pyridine plant is 62,000 tons per year [1] - Major raw materials for pyridine production include formaldehyde, acetaldehyde, and liquid ammonia, which are influenced by oil price fluctuations [1] Group 3: Product Composition and Market Focus - In the pyridine chain, pure pyridine accounts for 66.67% and 3-methylpyridine for 33.33% [1] - The company exports a significant portion of its paraquat products, indicating a strong export focus [1] Group 4: Future Development and Strategic Initiatives - The company plans to invest in a financing leasing company in the Shanghai Free Trade Zone to enhance its core competitiveness and optimize financing structures [2] - Future development will focus on accelerating the industrialization of downstream pyridine products and replacing high-toxicity pesticides [2] Group 5: Product Range and Alternatives - The pyridine chain can produce over 40 types of pesticide products, including various herbicides and insecticides [2]